Morning Versus Bedtime Dosing of Antihypertensive Medication

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

Also called NCT05089448

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Yan Li (from the registry)
Registry
  • NCT NCT05089448
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05089448. Randomized; no masking; primary purpose treatment. Start 2021-01-28 (actual); primary completion 2026-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Morning Versus Bedtime Dosing of Antihypertensive Medication
Condition
Hypertension
Condition
Blood Pressure
Condition
Drug Use
Intervention (Drug)
Alisartan, Amlodipine besylate
Intervention (Drug)
Alisartan, Amlodipine besylate
Lead sponsor
Yan Li (class: other)

Record details

Record id
cardio:ct-nct05089448
Content hash
7fbe53e3a5beb222442c5510a13280bd77c8a5ffe0c3d3e9eb163da5617dab12